Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression.
Angiotensin II
Cardiomyocyte hypertrophy
Empagliflozin
H9c2 cardiomyoblasts
NHE1
SGLT-1/2
Journal
Molecular and cellular biochemistry
ISSN: 1573-4919
Titre abrégé: Mol Cell Biochem
Pays: Netherlands
ID NLM: 0364456
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
12
01
2022
accepted:
10
03
2022
pubmed:
26
3
2022
medline:
7
5
2022
entrez:
25
3
2022
Statut:
ppublish
Résumé
Diabetes mellitus (DM)-induced cardiac morbidities have been the leading cause of death among diabetic patients. Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors including empagliflozin (EMPA), which have been approved for the treatment of DM, have gained attention for their cardioprotective effect. The mechanism by which SGLT-2 inhibitors exert their cardioprotective effect remains unclear. Recent studies have suggested that EMPA exerts its cardioprotective effect by inhibiting the Na
Identifiants
pubmed: 35334035
doi: 10.1007/s11010-022-04411-6
pii: 10.1007/s11010-022-04411-6
pmc: PMC9068664
doi:
Substances chimiques
Benzhydryl Compounds
0
Glucosides
0
Angiotensin II
11128-99-7
empagliflozin
HDC1R2M35U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1865-1872Subventions
Organisme : Qatar University
ID : QUST-2-CPH-2019-9
Informations de copyright
© 2022. The Author(s).
Références
Protein Cell. 2022 May;13(5):336-359
pubmed: 33417139
Cardiovasc Res. 2009 Oct 1;84(1):111-8
pubmed: 19509029
J Appl Physiol (1985). 2015 May 1;118(9):1154-60
pubmed: 25749446
Cardiovasc Diabetol. 2020 Apr 7;19(1):46
pubmed: 32264868
Sci Rep. 2017 Jan 27;7:41166
pubmed: 28128227
Front Physiol. 2018 Nov 21;9:1575
pubmed: 30519189
World J Diabetes. 2015 Jun 25;6(6):850-67
pubmed: 26131326
Eur J Pharmacol. 2020 Dec 5;888:173420
pubmed: 32781168
J Mol Cell Cardiol. 2013 Aug;61:77-82
pubmed: 23429008
Circulation. 2017 Oct 17;136(16):1548-1559
pubmed: 29038209
Cardiovasc Res. 2021 Dec 17;117(14):2794-2806
pubmed: 33135077
Diabetes Res Clin Pract. 2014 Feb;103(2):137-49
pubmed: 24630390
Circ Res. 1991 Dec;69(6):1476-86
pubmed: 1683272
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
In Vitro Cell Dev Biol Anim. 2011 Feb;47(2):125-31
pubmed: 21082279
Physiol Genomics. 2018 May 1;50(5):332-342
pubmed: 29473817
Hypertens Res. 2012 Apr;35(4):393-8
pubmed: 22072105
Pflugers Arch. 2015 Sep;467(9):1881-98
pubmed: 25304002
Mol Cell Biochem. 2015 Jun;404(1-2):211-20
pubmed: 25758355
Biomed Pharmacother. 2022 Feb;146:112515
pubmed: 34896968
Diabetologia. 2018 Mar;61(3):722-726
pubmed: 29197997
Cardiovasc Diabetol. 2017 Jan 13;16(1):9
pubmed: 28086951
Can J Cardiol. 2020 Apr;36(4):543-553
pubmed: 31837891
Diabetologia. 2017 Mar;60(3):568-573
pubmed: 27752710
J Biol Chem. 1999 Jul 16;274(29):20206-14
pubmed: 10400637
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Front Endocrinol (Lausanne). 2021 Oct 21;12:738848
pubmed: 34745006
Heart Fail Clin. 2019 Jul;15(3):341-347
pubmed: 31079692
Cardiovasc Diabetol. 2019 Jul 1;18(1):85
pubmed: 31262297
PLoS One. 2015 Apr 01;10(4):e0122230
pubmed: 25830299
Herz. 2014 May;39(3):390-6
pubmed: 23784363
Physiol Genomics. 2010 Aug;42(3):374-83
pubmed: 20460605
Nephrol Dial Transplant. 2019 Feb 1;34(2):208-230
pubmed: 30753708
JACC Basic Transl Sci. 2019 Oct 23;4(7):831-840
pubmed: 31998851
ESC Heart Fail. 2020 Sep 18;:
pubmed: 32946200